Shares of Indian pharmaceutical major Wockhardt rallied more than 13% on Monday after it announced a milestone development in its innovation pipeline: the United States Food and Drug Administration has formally accepted its New Drug Application for Zaynich, a novel antibiotic designed to target complicated urinary tract infections caused by multi-drug resistant gram-negative bacteria.
The stock touched Rs 1,384 apiece on Monday, snapping a two-session losing streak and signaling renewed investor confidence around the company’s research-led drug portfolio.
A transformative regulatory landmark
In its exchange filing, Wockhardt described the NDA acceptance as a “transformative moment, not only for Wockhardt, but also for the entire Indian pharmaceutical industry.”
The drug application was first submitted on September 30.
“This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA,” it added.
The FDA has also granted fast-track designation to Zaynich, reflecting its potential to address urgent unmet clinical needs in patients suffering from infections where standard treatment options have failed.
The priority review classification is expected to expedite regulatory timelines, bringing the drug closer to potential approval and commercial launch.
Wockhardt said the recognition underscores confidence in its scientific approach and could open a pathway for more research-origin products from Indian companies to enter global markets.
A decade-long research effort
The development of Zaynich began in 2011, driven by a program focused on anti-infective therapies for high-risk hospital-acquired infections.
The company said the candidate works through a novel beta-lactam enhancer mechanism that has drawn international interest due to its strong efficacy against highly resistant gram-negative pathogens, organisms responsible for extended hospital stays and high mortality across regions.
Compassionate-use cases in India and the US have already demonstrated clinical benefit in critically ill patients, according to the company.
Wockhardt said this step reinforces its mission to advance next-generation anti-infective therapies amid growing global concern around antimicrobial resistance.
“The FDA’s acceptance of the Zaynich NDA is a historic and proud moment for the organization and for India. It reaffirms our commitment to developing advanced anti-infective solutions for the world and demonstrates what Indian science and innovation can achieve on the global stage,” Workhardt said.
Commercial prospects and financial positioning
With more than 8 million cUTI cases reported annually across the US and EU, Wockhardt estimates the target market for gram-negative infections at over $7 billion.
It plans to independently commercialise Zaynich in the US, while keeping strategic partnerships open.
A successful launch could meaningfully expand its international footprint and strengthen revenue visibility, particularly in the European markets where it already has a strong presence.
The company currently trades at an RSI level of 54, indicating neutral sentiment.
In the second quarter ended September 2025, it reported a consolidated profit after tax of Rs 82 crore, reversing a Rs 16 crore loss in the same period last year.
India revenue rose 3% to Rs 172 crore, while UK revenue grew 4% to Rs 313 crore.
The NDA acceptance represents an unprecedented moment for Indian pharmaceutical R&D, placing Wockhardt at the centre of global attention as regulators evaluate what could become one of the first blockbuster anti-infectives developed from India for the world.
The post Wockhardt jump 13% as US FDA accepts NDA for Zaynich antibiotic in key milestone for Indian pharma appeared first on Invezz
